Skip to content
Review

Drug-Coated Balloons Versus Drug-Eluting Stents in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis With Reconstructed Individual Patient Data and GRADE Assessment.

Nov 2026 · Cardiology in Review · 0 citations · 38 references
Medicine

Abstract

Patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI) face high ischemic and bleeding risks. Drug-coated balloons (DCB) avoid a permanent implant and permit shorter dual antiplatelet therapy. We searched PubMed, Embase, Scopus, and Web of Science through May 2026 for studies comparing DCB with drug-eluting stents (DES) in adults with CKD undergoing PCI. Study-level hazard ratios (HRs) were pooled with random-effects inverse-variance models; individual patient data (IPD) were reconstructed from published Kaplan-Meier curves, and certainty was rated with Grading of Recommendations Assessment, Development and Evaluation. Five studies (two prespecified CKD analyses of randomized trials and three cohorts) comprising 2527 patients (1149 DCB and 1378 DES) were included. DCB and DES did not differ in the composite of major adverse cardiovascular or device-oriented events [HR 0.98; 95% confidence interval (CI), 0.77-1.24; IPD HR 0.96; 95% CI, 0.74-1.25], target-lesion revascularization (HR 1.02; 95% CI, 0.73-1.42), cardiac death (HR 0.94; 95% CI, 0.64-1.39), or myocardial infarction (HR 0.62; 95% CI, 0.36-1.06). Major bleeding did not differ significantly (HR 0.39; 95% CI, 0.13-1.17; IPD HR 0.51; 95% CI, 0.25-1.02). Stent or lesion thrombosis occurred only after DES (0/594 vs 12/810). Certainty was moderate for the composite endpoint and low for other outcomes.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.